

IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:

GRITSTONE BIO, INC.,¹

Debtor.

Chapter 11

Case No. 24-12305 (KBO)

Related Docket No. 309

**CERTIFICATION OF COUNSEL REGARDING
AMENDED FOURTH OMNIBUS MOTION FOR THE ENTRY OF AN ORDER (A)
AUTHORIZING REJECTION OF EXECUTORY CONTRACTS EFFECTIVE AS OF
THE APPLICABLE REJECTION DATE; (B) ABANDONING ANY REMAINING
PERSONAL PROPERTY; AND (C) GRANTING RELATED RELIEF**

The undersigned hereby certifies that:

1. On December 24, 2024, the above-captioned debtor and debtor in possession (the “Debtor”) filed the *Amended Fourth Omnibus Motion for the Entry of an Order (A) Authorizing Rejection of Executory Contracts Effective as of the Applicable Rejection Date; (B) Abandoning any Remaining Personal Property; and (C) Granting Related Relief* [Docket No. 309] (the “Motion”).

2. Pursuant to the *Notice of Amended Fourth Omnibus Motion for the Entry of an Order (A) Authorizing Rejection of Executory Contracts Effective as of the Applicable Rejection Date; (B) Abandoning any Remaining Personal Property; and (C) Granting Related Relief* [Docket No. 309-1], objections to entry of an order granting the Motion were due no later than January 7, 2025, at 4:00 p.m. Eastern Time (the “Objection Deadline”).

3. In response to filing the Motion, the Debtor received a request from Seattle Project Corp. (“SPC”) (the buyer of substantially all its assets) to remove certain contracts from this

¹ The Debtor’s mailing address is 4698 Willow Road, Pleasanton, CA 94588, and the last four digits of the Debtor’s federal tax identification number is 9534.



2412305250311000000000005

Motion so that they may be assumed and assigned to SPC. To the extent the Debtor received objections or informal objections from other parties, and, in each case, the Debtor removed all such contracts from this Motion as reflected on the revised exhibit accordingly. No other party filed an answer, objection, or other responsive pleading to the Motion on the Court's docket.

4. On December 31, 2024, the Debtor filed the *Notice of Provisional Removal of Contracts from Omnibus Motions for Rejection of Contracts* [Docket No. 326]. On January 29, 2025, the Debtor filed the *Second Notice of Provisional Removal of Contracts from Omnibus Motions for Rejection of Contracts* [Docket No. 386]. On February 14, 2025, the Debtor filed the *Third Notice of Provisional Removal of Contracts from Omnibus Motions for Rejection of Contracts* [Docket No. 456]. On March 6, 2025, the Debtor filed the *Fourth Notice of Provisional Removal of Contracts from Omnibus Motions for Rejection of Contracts* [Docket No. 494]. On March 7, 2025, the Debtor filed the *Fifth Notice of Provisional Removal of Contracts from Omnibus Motions for Rejection of Contracts* [Docket No. 496]. The exhibit to the attached proposed order was revised to the extent that any contract was listed on any of the forgoing provisional notices.

5. Attached hereto as **Exhibit A** is a revised proposed form of order rejecting the executory contracts identified on **Schedule 1** to **Exhibit A** and approving the Motion (the "**Proposed Order**").

6. A redlined copy of the Proposed Order is attached hereto as **Exhibit B**, showing changes to the Proposed Order when compared with the version submitted with the Motion.

7. Accordingly, the Debtor requests that the Proposed Order attached hereto as **Exhibit A** be entered at the Court's earliest convenience.

Dated: March 11, 2025

PACHULSKI STANG ZIEHL & JONES LLP

/s/ James E. O'Neill

Debra I. Grassgreen, (admitted *pro hac vice*)

John W. Lucas, (admitted *pro hac vice*)

Malhar S. Pagay, (admitted *pro hac vice*)

James E. O'Neill (DE Bar No. 4042)

919 North Market Street, 17th Floor

P.O. Box 8750

Wilmington, Delaware 19899-8705

Tel: 302-652-4100

Fax: 302-652-4400

Email: dgrassgreen@pszjlaw.com

jlucas@pszjlaw.com

mpagay@pszjlaw.com

joneill@pszjlaw.com

Counsel to the Debtor and Debtor in Possession

EXHIBIT A

Revised Proposed Order

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

GRITSTONE BIO, INC.,¹

Debtor.

Chapter 11

Case No. 24-12305 (KBO)

Related Docket No.: 309

**ORDER (A) AUTHORIZING THE AMENDED FOURTH OMNIBUS REJECTION
OF EXECUTORY CONTRACTS EFFECTIVE AS OF THE APPLICABLE
REJECTION DATE; (B) ABANDONING PERSONAL PROPERTY;
AND (C) GRANTING RELATED RELIEF**

Upon consideration of the *Amended Fourth Omnibus Motion for the Entry of an Order (A) Authorizing Rejection of Executory Contracts Effective as of the Applicable Rejection Date; and (B) Granting Related Relief* (the “Motion”)² of the above-captioned debtor and debtor in possession (the “Debtor”) for the entry of an order (this “Order”): (a) authorizing the Debtor to reject the Contracts effective as of the Rejection Effective Date listed on **Schedule 1** annexed hereto; (b) abandoning personal property; and (c) granting related relief, all as more fully set forth in the Motion; and upon consideration of the First Day Declaration; and the United States District Court for the District of Delaware having jurisdiction over this matter pursuant to 28 U.S.C. § 1334, which was referred to this Court under 28 U.S.C. § 157 pursuant to the *Amended Standing Order of Reference from the United States District Court for the District of Delaware*, dated February 29, 2012; and the Court having found that this is a core proceeding pursuant to 28 U.S.C. § 157(b)(2), and that the Court may enter a final order consistent with Article III of the United States Constitution; and the Court having found that venue of this proceeding and the Motion in this district is proper pursuant to 28 U.S.C. §§ 1408 and 1409; and the Court having found that the Debtor’s notice of the Motion and opportunity for a hearing on the Motion were appropriate under

¹ The Debtor’s mailing address is 4698 Willow Road, Pleasanton, CA 94588, and the last four digits of the Debtor’s federal tax identification number is 9534.

² Capitalized terms used but not defined herein have the meanings ascribed to them in the Motion.

the circumstances and no other notice need be provided; and the Court having reviewed the Motion and having heard the statements in support of the relief requested therein at a hearing before the Court (the “Hearing”); and the Court having determined that the legal and factual bases set forth in the Motion and at the Hearing establish just cause for the relief granted herein; and upon all of the proceedings had before the Court; and after due deliberation and sufficient cause appearing therefor;

IT IS HEREBY ORDERED THAT:

1. The Motion is **GRANTED** as set forth herein.
2. Pursuant to section 365 of the Bankruptcy Code, the Contracts, including any amendments, restatements, supplements, and associated statements of work associated with the Contracts, shall each be deemed rejected as of the Rejection Effective Date.
3. Within three (3) calendar days after entry of this Order, the Debtor will serve this Order on the counterparty to each Contract.
4. Counterparties to Contracts that are rejected pursuant to this Order must file a proof of claim relating to the rejection of such Contracts, if any, by the later of: (a) any applicable claims bar date established in this Chapter 11 Case; or (b) 30 days after entry of this Order. The Debtor reserves all rights to contest any such claim and to contest the characterization of each Contract as executory or not, and to contest whether such Contract may have terminated prior to the Petition Date or otherwise, or may not have been effective prior to the Petition Date or otherwise.
5. With respect to the Contracts listed on **Schedule 1** hereto, any personal property remaining with the counterparties to the Contracts as of the Rejection Effective Date shall be deemed abandoned and the landlord shall be free to dispose of such abandoned property in its sole and absolute discretion without notice or liability to the Debtor or any third parties.

6. The counterparties of any Contract rejected by this Order may use or dispose of the abandoned property in their sole and absolute discretion without notice or liability to the Debtor or its estate.

7. The Debtor reserves its right to assume, assign, or reject other executory contracts or unexpired leases, and nothing herein shall be deemed to affect such rights.

8. Notwithstanding the relief granted in this Order and any actions taken pursuant to such relief, nothing in this Order shall be deemed: (a) an admission as to the validity of any claim against the Debtor; (b) a waiver of the Debtor's right to dispute any claim on any grounds; (c) a promise or requirement to pay any claim; (d) an implication or admission that any particular claim is of a type specified or defined in this Order or the Motion; (e) a request or authorization to assume any agreement, contract, or lease pursuant to section 365 of the Bankruptcy Code; or (f) a waiver or limitation of the Debtor's right under the Bankruptcy Code or any other applicable law.

9. Notwithstanding the possible applicability of Rules 6004(g), 7062, or 9014 of the Federal Rules of Bankruptcy Procedure, or otherwise, the terms and conditions of this Order shall be immediately effective and enforceable upon its entry.

10. The Debtor is authorized to take all actions necessary to effectuate the relief granted in this Order in accordance with the Motion.

11. The Court retains exclusive jurisdiction with respect to all matters arising from or related to the implementation, interpretation, and enforcement of this Order.

SCHEDULE 1

Rejected Contracts¹

¹ For the avoidance of doubt, the listed Contracts, includes any amendments, restatements, supplements, and associated statements of work associated therewith, whether or not such amendments, restatements, supplements, and associated statements of work are listed in the schedule.

Counterparty	Contract/Lease Description	Date of Agreement	Effective Date
Element, Concord	Element, Concord - Services Agreement (One-time use) - Jan 01, 2024 (Q1 2024 Environmental Monitoring) - Amendment - Sep 30, 2024	9/30/2024	12/24/2024
Element, Concord	Element, Concord - Services Agreement (One-time use) - Aug 18, 2023 - Amendment - Feb 02, 2024	2/2/2024	12/24/2024
Element, Concord	Element, Concord - CDA - Nov 01, 2023	11/1/2023	12/24/2024
Element, Concord	Element, Concord - SOW - Oct 19, 2023	10/19/2023	12/24/2024
Element, Concord	Element, Concord - SOW - Oct 16, 2023	10/16/2023	12/24/2024
Eli Lilly and Company	Eli Lilly and Company - CDA - Sep 17, 2024	9/17/2024	12/24/2024
Elim Biopharmaceuticals, Inc.	Elim Biopharmaceuticals, Inc. - SOW - May 20, 2024	5/20/2024	12/24/2024
Elim Biopharmaceuticals, Inc.	Elim Biopharmaceuticals, Inc. - SOW - May 16, 2024	5/16/2024	12/24/2024
Elim Biopharmaceuticals, Inc.	Elim Biopharmaceuticals, Inc. - Master Services Agreement - May 16, 2024	5/16/2024	12/24/2024
Ellenberg & Ellenberg LLC	Ellenberg & Ellenberg LLC - CDA - Dec 20, 2023	12/20/2023	12/24/2024
EMD Millipore Corporation	EMD Millipore Corporation - SOW - Oct 29, 2021	10/29/2021	12/24/2024
EMD Millipore Corporation	Amendment - Mar 08, 2023	3/8/2023	12/24/2024
EMD Millipore Corporation	EMD Millipore Corporation - SOW - Oct 29, 2021 - Amendment - Oct 20, 2023	10/20/2023	12/24/2024
Employ, Inc	Employ, Inc - SOW - Feb 01, 2024 (2024 Subscription)	2/1/2024	12/24/2024
EpiVax, Inc.	EpiVax, Inc. - Master Services Agreement - Aug 18, 2022	8/18/2022	12/24/2024
EpiVax, Inc.	EpiVax, Inc - SOW - August 30, 2022 (WO #1))	8/30/2022	12/24/2024
EpiVax, Inc.	EpiVax, Inc. - Termination Letter - Aug 09, 2023 (WO #3)	8/9/2023	12/24/2024
EpiVax, Inc.	Epivax, Inc - CDA - May 06, 2022	5/6/2022	12/24/2024
EpiVax, Inc.	EpiVax, Inc. - SOW - Jun 29, 2023 (#4 - GO-010)	6/29/2023	12/24/2024
Eppendorf North America Inc.	Eppendorf North America Inc. - SOW - Jul 09, 2024 (additional pipette calibrations)	7/9/2024	12/24/2024
Eppendorf North America Inc.	Eppendorf North America Inc. - SOW - May 16, 2024 (2024 pipette calibrations)	5/16/2024	12/24/2024
Ernst and Young LLP	Ernst and Young LLP - Master Services Agreement - Apr 12, 2021	4/12/2021	12/24/2024
Ernst and Young LLP	Ernst and Young LLP - SOW - November 16, 2021	11/16/2021	12/24/2024
Ernst and Young LLP	Ernst and Young LLP - Services Agreement (One-time use) - Sep 13, 2024	9/13/2024	12/24/2024
Ernst and Young LLP	Ernst and Young LLP - Master Services Agreement	1/0/1900	12/24/2024

Counterparty	Contract/Lease Description	Date of Agreement	Effective Date
Eurofins Central Laboratory, LLC	Eurofins Central Laboratory, LLC - Services Agreement (one-time use) - March 22, 2023 (QA lot GRT-C9)	3/22/2023	12/24/2024
Eurofins EAG	Eurofins EAG - Services Agreement (One-time use) - Oct 04, 2023	10/4/2023	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - SOW - Mar 26, 2024 (IVAA testing for AU patient lot release)	3/26/2024	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - SOW - Sep 12, 2024 (Analytical testing for process residuals - Kanamycin)	9/12/2024	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - Quality Agreement - Jun 20, 2020	6/20/2020	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - SOW - May 06, 2024 (Testing of Gritstone's in-process samples and reporting results)	5/6/2024	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - CDA - May 14, 2019	5/14/2019	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - CDA - Feb 19, 2019	2/19/2019	12/24/2024
Evaluate Limited	Evaluate Ltd - Services Agreement (one-time use) - December 31, 2022	12/31/2022	12/24/2024
Evercore Group LLC	Evercore Group L.L.C - Other - April 05, 2022 (Engagement Letter))	3/28/2022	12/24/2024
EVERSANA Life Science Services, LLC	EVERSANA Life Science Services, LLC - CDA - Oct 17, 2023 (Potential Business Relationship)	10/17/2023	12/24/2024
Exact Sciences Corporation	Exact Sciences Corporation - CDA - Mar 28, 2024	3/28/2024	12/24/2024
Exscientia AI Limited	Exscientia AI Limited - CDA - Nov 01, 2023	11/1/2023	12/24/2024
F. Hoffmann-LaRoche Ltd	F. Hoffmann-LaRoche Ltd - Other - October 15, 2021 (Clinical Supply Agreement Supplement (GO-010)))	10/15/2021	12/24/2024
Feridoun Fahiminia	Feridoun Fahiminia - CDA - Feb 22, 2021	2/22/2021	12/24/2024
Fidelity Workplace Services LLC	Fidelity Workplace Services LLC - Services Agreement (one-time use) - July 01, 2022)	7/1/2022	12/24/2024
Fidelity Workplace Services LLC	Fidelity Workplace Services LLC - Other (Addition of QDRO Service)	1/0/1900	12/24/2024
Fidelity Workplace Services LLC	FMR LLC dba Fidelity Institutional Asset Management - Other - January 01, 2023 - Amendment - Oct 18, 2024	10/18/2024	12/24/2024
FlowJO	FlowJO - License Agreement - Aug 08, 2024 (SW FlowJo Com Portal Licenses)	8/8/2024	12/24/2024
FMR LLC dba Fidelity Institutional Asset Management	FMR LLC dba Fidelity Institutional Asset Management - Other - January 01, 2023	1/1/2023	12/24/2024
Focus Technology	Focus Technology - Master Services Agreement - Sep 20, 2022	9/20/2022	12/24/2024

Counterparty	Contract/Lease Description	Date of Agreement	Effective Date
Fosun Pharma USA Inc.	Fosun Pharma USA Inc - CDA - July 20, 2022	7/20/2022	12/24/2024
Foundation Medicine, Inc	Foundation Medicine, Inc - CDA - Jul 10, 2024	7/10/2024	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - SOW - Jun 01, 2023	6/1/2023	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - Master Services Agreement - Jun 01, 2023	6/1/2023	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - Master Services Agreement - Jun 01, 2023 - Amendment - Apr 26, 2024	4/26/2024	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - Master Services Agreement - Jun 01, 2023 - Amendment - Jan 16, 2024	1/16/2024	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - CDA - Jun 26, 2024 (Potential Investigator Trial for Sars-CoV-2)	6/26/2024	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - CDA - Dec 06, 2023 (GO-015)	12/6/2023	12/24/2024
Friends of Cancer Research	Friends of Cancer Research - Other - Jul 12, 2023	7/12/2023	12/24/2024
Fujifilm Irvine Scientific	Fujifilm Irvine Scientific - CDA - Jun 14, 2023	6/14/2023	12/24/2024
Future Solution Investments LLC	Future Solution Investments LLC - CDA - Sep 11, 2024	9/11/2024	12/24/2024
G42 Health Care AI Holding RSC Ltd	G42 Health Care AI Holding RSC Ltd - CDA - Jun 10, 2020	6/10/2020	12/24/2024
Galapagos	Galapagos - CDA - Apr 30, 2024	4/30/2024	12/24/2024
Gardeners Guild Inc.	Gardeners Guild Inc - Amendment - January 01, 2023 (AMND 1 to SER)) - Amendment - Jan 01, 2024	1/1/2024	12/24/2024

EXHIBIT B

Redline

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

GRITSTONE BIO, INC.,¹

Debtor.

Chapter 11

Case No. 24-12305 (KBO)

Related Docket No.:

**ORDER (A) AUTHORIZING THE AMENDED FOURTH OMNIBUS REJECTION
OF EXECUTORY CONTRACTS EFFECTIVE AS OF THE APPLICABLE
REJECTION DATE; (B) ABANDONING PERSONAL PROPERTY;
AND (C) GRANTING RELATED RELIEF**

Upon consideration of the *Amended Fourth Omnibus Motion for the Entry of an Order (A) Authorizing Rejection of Executory Contracts Effective as of the Applicable Rejection Date; and (B) Granting Related Relief* (the “Motion”)² of the above-captioned debtor and debtor in possession (the “Debtor”) for the entry of an order (this “Order”): (a) authorizing the Debtor to reject the Contracts effective as of the Rejection Effective Date listed on **Schedule 1** annexed hereto; (b) abandoning personal property; and (c) granting related relief, all as more fully set forth in the Motion; and upon consideration of the First Day Declaration; and the United States District Court for the District of Delaware having jurisdiction over this matter pursuant to 28 U.S.C. § 1334, which was referred to this Court under 28 U.S.C. § 157 pursuant to the *Amended Standing Order of Reference from the United States District Court for the District of Delaware*, dated February 29, 2012; and the Court having found that this is a core proceeding pursuant to 28 U.S.C. § 157(b)(2), and that the Court may enter a final order consistent with Article III of the United States Constitution; and the Court having found that venue of this proceeding and the Motion in this district is proper pursuant to 28 U.S.C. §§ 1408 and 1409; and the Court having found that the Debtor’s notice of the Motion and opportunity for a hearing on the Motion were appropriate under

¹ The Debtor’s mailing address is 4698 Willow Road, Pleasanton, CA 94588, and the last four digits of the Debtor’s federal tax identification number is 9534.

² Capitalized terms used but not defined herein have the meanings ascribed to them in the Motion.

the circumstances and no other notice need be provided; and the Court having reviewed the Motion and having heard the statements in support of the relief requested therein at a hearing before the Court (the “Hearing”); and the Court having determined that the legal and factual bases set forth in the Motion and at the Hearing establish just cause for the relief granted herein; and upon all of the proceedings had before the Court; and after due deliberation and sufficient cause appearing therefor;

IT IS HEREBY ORDERED THAT:

1. The Motion is **GRANTED** as set forth herein.
2. Pursuant to section 365 of the Bankruptcy Code, the Contracts, including any amendments, restatements, supplements, and associated statements of work associated with the Contracts, shall each be deemed rejected as of the Rejection Effective Date.
3. Within three (3) calendar days after entry of this Order, the Debtor will serve this Order on the counterparty to each Contract.
4. Counterparties to Contracts that are rejected pursuant to this Order must file a proof of claim relating to the rejection of such Contracts, if any, by the later of: (a) any applicable claims bar date established in this Chapter 11 Case; or (b) 30 days after entry of this Order. The Debtor reserves all rights to contest any such claim and to contest the characterization of each Contract as executory or not, and to contest whether such Contract may have terminated prior to the Petition Date or otherwise, or may not have been effective prior to the Petition Date or otherwise.
5. With respect to the Contracts listed on **Schedule 1** hereto, any personal property remaining with the counterparties to the Contracts as of the Rejection Effective Date shall be deemed abandoned and the landlord shall be free to dispose of such abandoned property in its sole and absolute discretion without notice or liability to the Debtor or any third parties.

6. The counterparties of any Contract rejected by this Order may use or dispose of the abandoned property in their sole and absolute discretion without notice or liability to the Debtor or its estate.

7. The Debtor reserves its right to assume, assign, or reject other executory contracts or unexpired leases, and nothing herein shall be deemed to affect such rights.

8. Notwithstanding the relief granted in this Order and any actions taken pursuant to such relief, nothing in this Order shall be deemed: (a) an admission as to the validity of any claim against the Debtor; (b) a waiver of the Debtor's right to dispute any claim on any grounds; (c) a promise or requirement to pay any claim; (d) an implication or admission that any particular claim is of a type specified or defined in this Order or the Motion; (e) a request or authorization to assume any agreement, contract, or lease pursuant to section 365 of the Bankruptcy Code; or (f) a waiver or limitation of the Debtor's right under the Bankruptcy Code or any other applicable law.

9. Notwithstanding the possible applicability of Rules 6004(g), 7062, or 9014 of the Federal Rules of Bankruptcy Procedure, or otherwise, the terms and conditions of this Order shall be immediately effective and enforceable upon its entry.

10. The Debtor is authorized to take all actions necessary to effectuate the relief granted in this Order in accordance with the Motion.

11. The Court retains exclusive jurisdiction with respect to all matters arising from or related to the implementation, interpretation, and enforcement of this Order.

SCHEDULE 1

Rejected Contracts¹

¹ For the avoidance of doubt, the listed Contracts, includes any amendments, restatements, supplements, and associated statements of work associated therewith, whether or not such amendments, restatements, supplements, and associated statements of work are listed in the schedule.

Counterparty	Contract/Lease Description	Date of Agreement	Effective Date
Element, Concord	Element, Concord - Services Agreement (One-time use) - Jan 01, 2024 (Q1 2024 Environmental Monitoring) - Amendment - Sep 30, 2024	9/30/2024	12/24/2024
Element, Concord	Element, Concord - Services Agreement (One-time use) - Aug 18, 2023 - Amendment - Feb 02, 2024	2/2/2024	12/24/2024
Element, Concord	Element, Concord - CDA - Nov 01, 2023	11/1/2023	12/24/2024
Element, Concord	Element, Concord - SOW - Oct 19, 2023	10/19/2023	12/24/2024
Element, Concord	Element, Concord - SOW - Oct 16, 2023	10/16/2023	12/24/2024
Eli Lilly and Company	Eli Lilly and Company - CDA - Sep 17, 2024	9/17/2024	12/24/2024
Elim Biopharmaceuticals, Inc.	Elim Biopharmaceuticals, Inc. - SOW - May 20, 2024	5/20/2024	12/24/2024
Elim Biopharmaceuticals, Inc.	Elim Biopharmaceuticals, Inc. - SOW - May 16, 2024	5/16/2024	12/24/2024
Elim Biopharmaceuticals, Inc.	Elim Biopharmaceuticals, Inc. - Master Services Agreement - May 16, 2024	5/16/2024	12/24/2024
Ellenberg & Ellenberg LLC	Ellenberg & Ellenberg LLC - CDA - Dec 20, 2023	12/20/2023	12/24/2024
EMD Millipore Corporation	EMD Millipore Corporation - SOW - Oct 29, 2021	10/29/2021	12/24/2024
EMD Millipore Corporation	Amendment - Mar 08, 2023	3/8/2023	12/24/2024
EMD Millipore Corporation	EMD Millipore Corporation - SOW - Oct 29, 2021 - Amendment - Oct 20, 2023	10/20/2023	12/24/2024
Emery Station Joint Venture, LLC	Emery Station Joint Venture, LLC - Other - Oct 29, 2019	10/29/2019	12/24/2024
Emery Station Joint Venture, LLC	Emery Station Joint Venture, LLC - Other - Jul 26, 2019	7/26/2019	12/24/2024
Emery Station Joint Venture, LLC	Emery Station Joint Venture, LLC - Other - Feb 01, 2019	2/1/2019	12/24/2024
Emery Station Joint Venture, LLC	Emery Station Joint Venture, LLC - Other - Jan 28, 2019	1/28/2019	12/24/2024
Emery Station Joint Venture, LLC	Emery Station Joint Venture, LLC - Other - Feb 01, 2019 - Amendment - Oct 24, 2024	10/24/2024	12/24/2024
Employ, Inc	Employ, Inc - SOW - Feb 01, 2024 (2024 Subscription)	2/1/2024	12/24/2024
EpiVax, Inc.	EpiVax, Inc. - Master Services Agreement - Aug 18, 2022	8/18/2022	12/24/2024
EpiVax, Inc.	EpiVax, Inc - SOW - August 30, 2022 (WO #1))	8/30/2022	12/24/2024
EpiVax, Inc.	EpiVax, Inc. - Termination Letter - Aug 09, 2023 (WO #3)	8/9/2023	12/24/2024
EpiVax, Inc.	Epivax, Inc - CDA - May 06, 2022	5/6/2022	12/24/2024
EpiVax, Inc.	EpiVax, Inc. - SOW - Jun 29, 2023 (#4 - GO-010)	6/29/2023	12/24/2024
Eppendorf North America Inc.	Eppendorf North America Inc. - SOW - Jul 09, 2024 (additional pipette calibrations)	7/9/2024	12/24/2024
Eppendorf North America Inc.	Eppendorf North America Inc. - SOW -	5/16/2024	12/24/2024

	May 16, 2024 (2024 pipette calibrations)		
Ernst and Young LLP	Ernst and Young LLP - Master Services Agreement - Apr 12, 2021	4/12/2021	12/24/2024
Ernst and Young LLP	Ernst and Young LLP - SOW - November 16, 2021	11/16/2021	12/24/2024
Ernst and Young LLP	Ernst and Young LLP - Services Agreement (One-time use) - Sep 13, 2024	9/13/2024	12/24/2024
Ernst and Young LLP	Ernst and Young LLP - Master Services Agreement	1/0/1900	12/24/2024
Eurofins Central Laboratory, LLC	Eurofins Central Laboratory, LLC - Services Agreement (one-time use) - March 22, 2023 (QA lot GRT-C9)	3/22/2023	12/24/2024
Eurofins EAG	Eurofins EAG - Services Agreement (One-time use) - Oct 04, 2023	10/4/2023	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - SOW - Mar 26, 2024 (IVAA testing for AU patient lot release)	3/26/2024	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - SOW - Sep 12, 2024 (Analytical testing for process residuals - Kanamycin)	9/12/2024	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - Quality Agreement - Jun 20, 2020	6/20/2020	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - SOW - May 06, 2024 (Testing of Gritstone's in-process samples and reporting results)	5/6/2024	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - CDA - May 14, 2019	5/14/2019	12/24/2024
Eurofins Lancaster Laboratories, Inc.	Eurofins Lancaster Laboratories, Inc. - CDA - Feb 19, 2019	2/19/2019	12/24/2024
Evaluate Limited	Evaluate Ltd - Services Agreement (one-time use) - December 31, 2022	12/31/2022	12/24/2024
Evercore Group LLC	Evercore Group L.L.C - Other - April 05, 2022 (Engagement Letter))	3/28/2022	12/24/2024
EVERSANA Life Science Services, LLC	EVERSANA Life Science Services, LLC - CDA - Oct 17, 2023 (Potential Business Relationship)	10/17/2023	12/24/2024
Exact Sciences Corporation	Exact Sciences Corporation - CDA - Mar 28, 2024	3/28/2024	12/24/2024
Exscientia AI Limited	Exscientia AI Limited - CDA - Nov 01, 2023	11/1/2023	12/24/2024
F. Hoffmann-LaRoche Ltd	F. Hoffmann-LaRoche Ltd - Other - October 15, 2021 (Clinical Supply Agreement Supplement (GO-010)))	10/15/2021	12/24/2024
Feridoun Fahiminia	Feridoun Fahiminia - CDA - Feb 22, 2021	2/22/2021	12/24/2024
Fidelity Workplace Services LLC	Fidelity Workplace Services LLC - Services Agreement (one-time use) - July 01, 2022)	7/1/2022	12/24/2024
Fidelity Workplace Services LLC	Fidelity Workplace Services LLC - Other (Addition of QDRO Service)	1/0/1900	12/24/2024
Fidelity Workplace Services LLC	FMR LLC dba Fidelity Institutional Asset Management - Other - January 01, 2023 - Amendment - Oct 18, 2024	10/18/2024	12/24/2024
FirstHealth of the Carolinas, Inc.	FirstHealth of the Carolinas, Inc. - CTA	7/15/2022	12/24/2024

	July 15, 2022 (GO-010))		
Fisher Bioservices Inc.	Fisher BioServices Inc. Master Services Agreement - Apr 21, 2021	4/21/2021	12/24/2024
Fisher Bioservices Inc.	Fisher BioServices Inc. Master Services Agreement - Oct 22, 2018	10/22/2018	12/24/2024
Fisher Bioservices Inc.	Fisher BioServices Inc. Master Services Agreement - Oct 02, 2018	10/2/2018	12/24/2024
Fisher Bioservices Inc.	Fisher BioServices Inc. Master Services Agreement - Aug 10, 2018	8/10/2018	12/24/2024
Fisher Bioservices Inc.	Fisher Bioservices Inc. SOW - Sep 26, 2023 (GO-015)	9/26/2023	12/24/2024
Fisher Bioservices Inc.	Fisher Bioservices Inc. SOW - Aug 09, 2023	8/9/2023	12/24/2024
Fisher Bioservices Inc.	Fisher Bioservices Inc. SOW - Apr 24, 2024	4/24/2024	12/24/2024
Fisher Bioservices Inc.	Fisher Bioservices Inc. Quality Agreement - Jun 13, 2018	6/13/2018	12/24/2024
Fisher Bioservices Inc.	Fisher BioServices Inc. Other - Oct 15, 2019	10/15/2019	12/24/2024
Fisher Bioservices Inc.	Amendment - Feb 17, 2023	2/17/2023	12/24/2024
Fisher Bioservices Inc.	Amendment - Mar 16, 2022	3/16/2022	12/24/2024
Fisher Bioservices Inc.	Amendment - Jan 12, 2022	1/12/2022	12/24/2024
Fisher Bioservices Inc.	Amendment - Oct 21, 2021	10/21/2021	12/24/2024
Fisher Bioservices Inc.	Amendment Aug 13, 2021	8/13/2021	12/24/2024
Fisher Bioservices Inc.	Fisher Bioservices Inc. SOW - Mar 13, 2018	3/13/2018	12/24/2024
FlowJO	FlowJO - License Agreement - Aug 08, 2024 (SW FlowJo Com Portal Licenses)	8/8/2024	12/24/2024
FMR LLC dba Fidelity Institutional Asset Management	FMR LLC dba Fidelity Institutional Asset Management - Other - January 01, 2023	1/1/2023	12/24/2024
Focus Technology	Focus Technology - Master Services Agreement - Sep 20, 2022	9/20/2022	12/24/2024
Fosun Pharma USA Inc.	Fosun Pharma USA Inc - CDA - July 20, 2022	7/20/2022	12/24/2024
Foundation Medicine, Inc	Foundation Medicine, Inc - CDA - Jul 10, 2024	7/10/2024	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - SOW - Jun 01, 2023	6/1/2023	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - Master Services Agreement - Jun 01, 2023	6/1/2023	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - Master Services Agreement - Jun 01, 2023 - Amendment - Apr 26, 2024	4/26/2024	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - Master Services Agreement - Jun 01, 2023 - Amendment - Jan 16, 2024	1/16/2024	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - CDA - Jun 26, 2024 (Potential Investigator Trial for Sars-CoV-2)	6/26/2024	12/24/2024
Fred Hutchinson Cancer Research Center	Fred Hutchinson Cancer Research Center - CDA - Dec 06, 2023 (GO-015)	12/6/2023	12/24/2024
Friends of Cancer Research	Friends of Cancer Research - Other -	7/12/2023	12/24/2024

	Jul 12, 2023		
Fujifilm Irvine Scientific	Fujifilm Irvine Scientific - CDA - Jun 14, 2023	6/14/2023	12/24/2024
Future Solution Investments LLC	Future Solution Investments LLC - CDA - Sep 11, 2024	9/11/2024	12/24/2024
G42 Health Care AI Holding RSC Ltd	G42 Health Care AI Holding RSC Ltd - CDA - Jun 10, 2020	6/10/2020	12/24/2024
Galapagos	Galapagos - CDA - Apr 30, 2024	4/30/2024	12/24/2024
Gardeners Guild Inc.	Gardeners' Guild Inc - Amendment - January 01, 2023 (AMND 1 to SER)) - Amendment - Jan 01, 2024	1/1/2024	12/24/2024
Genevant Sciences Corporation	(3-party NDA with Genevant and Merck Cie)) - Amendment - Jul 28, 2023	7/28/2023	12/24/2024
Genevant Sciences GmbH	Genevant Sciences GmbH - License Agreement - Aug 10, 2023 - Amendment - Aug 09, 2024	8/9/2024	12/24/2024
Genevant Sciences GmbH	Genevant Sciences GmbH - SOW - Jul 15, 2024	7/15/2024	12/24/2024
Genevant Sciences GmbH	Genevant Sciences GmbH - License Agreement - Aug 10, 2023	8/10/2023	12/24/2024
Genevant Sciences GmbH	Genevant Sciences GmbH - License Agreement - Oct 20, 2020	Jan 29 2021	12/24/2024
Genevant Sciences GmbH	Genevant Sciences GmbH - License Agreement - Oct 21, 2020	10/21/2020	12/24/2024
Genevant Sciences GmbH	Genevant Sciences GmbH - License Agreement - Oct 21, 2020 - Amendment - Aug 14, 2023	8/14/2023	12/24/2024
Genevant Sciences GmbH c_o Genevant Sciences Corporation	Genevant Sciences GmbH c_o Genevant Sciences Corporation - Other - March 15, 2022 (Gritstone bio and)	3/15/2022	12/24/2024
Genevant Sciences, Inc.	Genevant Sciences, Inc. - License Agreement - Jan 15, 2021	1/15/2021	12/24/2024